LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZ·NASDAQ

$7.01

-0.14%
HealthcareBiotechnology

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

At a Glance

Live Snapshot
Market Cap$219.79M
EPS-2.8500
P/E Ratio-2.46
Earnings Date07/29/2026

lenz

Cost of Revenue

Last Annual Value

418.00K

3-Year CAGR

%

5-Year CAGR

28%

10-Year CAGR

%

LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Competitors Analysis of Cost of Revenue

LENZ · NASDAQ
CompanyCost of Revenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
418.00K
N/A-10.6%N/A 
SVRA logo
Savara Inc.
NASDAQ:SVRA
245.00K
-82.3%-61.5%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
0.00
N/AN/AN/A
20.42M
N/A149.1%N/A
363.00K
N/AN/A-40.1%
4.75M
N/AN/A-10.7%
152.35M
0.8%1.6%N/A
546.00K
N/AN/AN/A
7.32M
N/AN/AN/A
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Fair Value Envelope

LENZ · NASDAQ

Our analysis suggests that LENZ has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.01, this represents a potential HIDDEN relative to our calculated worth for LENZ Therapeutics, Inc..

Intrinsic Value
Current Price: $7.01